COX-2 Gastrointestinal Safety Profile Called Into Question By BMJ Study
This article was originally published in The Tan Sheet
Executive Summary
COX-2 inhibitors do not provide improved safety against gastrointestinal adverse events compared to non-steroidal anti-inflammatory drugs, according to a study published in the Online First edition of the British Medical Journal Dec. 2
You may also be interested in...
Avoiding GMP “Showstoppers” Keeps Manufacturers Off FDA’s “Radar”
Compliance consultants warn that certain dietary supplement good manufacturing practices violations are inspection "showstoppers" and will draw agency enforcement
Avoiding GMP “Showstoppers” Keeps Manufacturers Off FDA’s “Radar”
Compliance consultants warn that certain dietary supplement good manufacturing practices violations are inspection "showstoppers" and will draw agency enforcement
Chattem’s Financing Strategy Keeps Door Open For Acquisitions
Chattem remains in the hunt for acquisitions because its preferred financing strategy continues to be attractive even with lending activity slowed worldwide, according to President and Chief Operating Officer Bob Bosworth